10.1016/j.bmcl.2005.07.052
The research focuses on the synthesis of [1,2,4]triazolo[1,5-a]pyrazines as potential adenosine A2A receptor antagonists, which are of interest due to their therapeutic potential in treating Parkinson's disease. The purpose of the study was to develop selective A2A antagonists that could improve target affinity, selectivity, and in vivo activity, potentially offering a means to control immunological, cardiovascular, renal, or neurological responses for therapeutic benefit. The researchers synthesized a series of these antagonists using a novel route, starting from 2-amino-3,5-dibromopyrazine (7) and employing oxidative cyclization with reagents such as AlCl3 and Pb(OAc)4 to form the [1,2,4]triazolo[1,5-a]pyrazine nucleus.